Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04142619 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
A Phase 1 study, sponsored by Cellectis S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04142619 is a Phase 1 study that was terminated before completion, run by Cellectis S.A.. The registered enrollment target is 11 participants.
The verdict
NCT04142619, a Phase 1 study, was terminated before completion, sponsored by Cellectis S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).
Interventions
- BIOLOGICAL UCARTCS1A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2023-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04142619
The ClinicalTrials.gov registry entry for NCT04142619 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellectis S.A., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UCARTCS1A is the first listed.
NCT04142619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04142619 about?
NCT04142619 is a clinical study titled "Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)". This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated...
What is the current status of trial NCT04142619?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-11-21. Estimated completion is 2023-06-18.
What interventions are being tested in trial NCT04142619?
The interventions under investigation include: UCARTCS1A (BIOLOGICAL).
Who is sponsoring clinical trial NCT04142619?
This trial is sponsored by Cellectis S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.